We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00517101
Recruitment Status : Unknown
Verified August 2007 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : August 16, 2007
Last Update Posted : August 16, 2007
Sponsor:
Information provided by:
Tel-Aviv Sourasky Medical Center

Brief Summary:

A relationship between IBD and spondyloarthropathy is well recognized. ASCA ( anti saccharomyces cerevisiae antibodies)are considered to be a serological marker for Crohn's disease and have been studied in patients with spondyloarthropathy with conflicting results. More recently, new serological markers for IBD have been described. These markers are antibodies to certain defined glycans , and their use may permit an improved diagnosis of IBD.

The aim of our study is to investigate wether these new serological markers are present in the sera of patients with spondyloarthropathy.


Condition or disease
Psoriatic Arthritis Ankylosing Spondylitis Undifferentiated Spondyloarthropathy

Study Type : Observational
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
Study Start Date : September 2007






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • diagnosis of psoriatic arthritis, ankylosing spondylitis, or undifferentiated spondyloarthropathy

Exclusion Criteria:

  • diagnosed inflammatory bowel disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00517101


Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Investigators
Principal Investigator: valerie aloush, MD Tel-Aviv Sourasky Medical Center

ClinicalTrials.gov Identifier: NCT00517101     History of Changes
Other Study ID Numbers: TAMSC-07-VA-318-CTIL
First Posted: August 16, 2007    Key Record Dates
Last Update Posted: August 16, 2007
Last Verified: August 2007

Keywords provided by Tel-Aviv Sourasky Medical Center:
spondyloarthropathy
inflammatory bowel disease
antibodies

Additional relevant MeSH terms:
Spondylitis
Spondylitis, Ankylosing
Arthritis, Psoriatic
Spondylarthropathies
Spondylarthritis
Bone Diseases, Infectious
Infection
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Ankylosis
Joint Diseases
Arthritis
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Antibodies
Immunologic Factors
Physiological Effects of Drugs